Back

QRS length/left ventricular mass index: a novel predictive factor of response to cardiac resynchronization therapy

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Cardiac resynchronisation therapy - conduction system pacing 2 Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sebastian Sanhueza

Pontifical Catholic University of Chile, Santiago (Chile)

8 More presentations in this session

Presentation thumbnail
Tailored electrocardiographic-based criteria for different pacing locations within the left bundle branch
Doctor A. Estevez Paniagua (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
QRS transition during interrupted lead screwing-in to confirm left bundle branch capture during left bundle branch area pacing
Mr T. Manuel (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Left bundle fascicular versus left bundle trunk pacing: a comparison of their electrical synchrony parameters
Doctor A. Estevez Paniagua (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Impact of myocardial phenotype on atrioventricular delay optimization at rest and during exercise: insights from a virtual patient study
Miss C. Manetti (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Impact of left bundle branch block morphology in predicting response to left bundle branch area pacing for cardiac resynchronization therapy
Doctor M. Latorre (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac resynchronisation therapy - conduction system pacing 2

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
QRS index as a predictor of response to cardiac resynchronization therapy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Predictors of future need for cardiac resynchronization therapy (CRT) in HFrEF.
thumbnail
Congress Presentation
Frontal QRS-T angle identifies non-responders to cardiac resynchronisation therapy even among ideal candidates with heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources